Biodexa Pharmaceuticals (BDRX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Biodexa Pharmaceuticals PLC faces potential delisting from the Nasdaq Capital Market due to its stock price being below the required $1.00 threshold for 30 consecutive business days. The company plans to appeal this decision by requesting a hearing before the Nasdaq Hearings Panel, which will delay any suspension or delisting action. Biodexa is known for its innovative clinical-stage pipeline targeting diseases with unmet medical needs, including treatments for cancer and diabetes.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
